KFDA approves autologous stem cell therapy for patients with Crohn’s disease
Published: 2011-10-27 06:57:00
Updated: 2011-10-27 06:57:00
Anterogen, a Korean biotechnology venture, announced Tuesday that it will conduct phase I clinical trials in patients with Crohn’s disease with its autologous stem cell therapy from October 25 after obtaining its final approval from the Korea Food and Drug Administration.
Crohn’s disease cause...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
